12:00 AM
 | 
Dec 18, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Escitalopram: Phase III

In a Phase III trial of 366 patients with major depressive disorder, 10 mg/day and 20 mg/day doses of escitalopram gave a significant improvement in clinical measures of depression over 8 weeks of...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >